Currently, there are 61.17M common shares owned by the public and among those 53.88M shares have been available to trade.
The company’s stock has a 5-day price change of 22.15% and 17.74% over the past three months. SAGE shares are trading 38.12% year to date (YTD), with the 12-month market performance down to -70.47% lower. It has a 12-month low price of $4.62 and touched a high of $28.26 over the same period. SAGE has an average intraday trading volume of 1.06 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 32.30%, 32.78%, and -19.58% respectively.
Institutional ownership of Sage Therapeutics Inc (NASDAQ: SAGE) shares accounts for 85.30% of the company’s 61.17M shares outstanding.
It has a market capitalization of $458.80M and a beta (3y monthly) value of 0.90. The earnings-per-share (ttm) stands at -$5.58. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.93% over the week and 7.75% over the month.
Earnings per share for the fiscal year are expected to increase by 28.60%, and 43.34% over the next financial year.
Looking at the support for the SAGE, a number of firms have released research notes about the stock. RBC Capital Mkts stated their Sector Perform rating for the stock in a research note on November 21, 2024, with the firm’s price target at $4. RBC Capital Mkts was of a view on October 04, 2024 that the stock is Sector Perform, while TD Cowen gave the stock Hold rating on July 30, 2024, issuing a price target of $16- $10. JP Morgan on their part issued Neutral rating on July 25, 2024.
